{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:00:44Z","timestamp":1792458044576,"version":"4.5.0"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>It is well-known that aminoglycoside antibiotics can cause significant hearing loss and vestibular deficits that have been described in animal studies and in clinical reports. The purpose of this review is to summarize relevant preclinical and clinical publications that discuss the ototoxicity of non-aminoglycoside antibiotics. The major classes of antibiotics other than aminoglycosides that have been associated with hearing loss in animal studies and in patients are discussed in this report. These antibiotics include: capreomycin, a polypeptide antibiotic that has been used to treat patients with drug-resistant tuberculosis, particularly in developing nations; the macrolides, including erythromycin, azithromycin and clarithromycin; and vancomycin. These antibiotics have been associated with ototoxicity, particularly in neonates. It is critical to be aware of the ototoxic potential of these antibiotics since so much attention has been given to the ototoxicity of aminoglycoside antibiotics in the literature.<\/jats:p>","DOI":"10.3389\/fneur.2021.652674","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T05:57:03Z","timestamp":1615269423000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":52,"title":["Ototoxicity of Non-aminoglycoside Antibiotics"],"prefix":"10.3389","volume":"12","author":[{"given":"Leonard P.","family":"Rybak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickram","family":"Ramkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashree","family":"Mukherjea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/j.1749-6632.1966.tb45535.x","article-title":"Chemical and physical characterization of capreomycin","volume":"135","author":"Herr","year":"1966","journal-title":"Ann N Y Acad Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1128\/AAC.00628-11","article-title":"Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin","volume":"55","author":"Akbergenov","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.idc.2010.05.001","article-title":"Extensively drug-resistant tuberculosis: epidemiology and management challenges","volume":"24","author":"Dheda","year":"2010","journal-title":"Infect Dis Clin North Am."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1472-6815-7-5","article-title":"Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up","volume":"7","author":"Duggal","year":"2007","journal-title":"BMC Ear Nose Throat Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40360-019-0313-y","article-title":"Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study","volume":"20","author":"Shibeshi","year":"2019","journal-title":"BMC Pharmacol Toxicol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e02586","DOI":"10.1128\/AAC.02586-16","article-title":"Adverse effects and choice between the injectable agents amikacin and capreomycin in multidrug-resistant tuberculosis","volume":"61","author":"Arnold","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e63057","DOI":"10.1371\/journal.pone.0063057","article-title":"Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa","volume":"8","author":"Shean","year":"2013","journal-title":"PLoS ONE."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/j.1749-6632.1966.tb45545.x","article-title":"Toxicology studies in patients on prolonged therapy with capreomycin","volume":"135","author":"Miller","year":"1966","journal-title":"Ann N Y Acad Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/j.1749-6632.1966.tb45543.x","article-title":"Capreomycin in the treatment of pulmonary tuberculosis","volume":"135","author":"Donomae","year":"1966","journal-title":"Ann N Y Acad Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/jac\/dkr221","article-title":"Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice","volume":"66","author":"Sturdy","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1136\/thoraxjnl-2015-207374","article-title":"Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia\u2013an observational cohort study","volume":"70","author":"Meressa","year":"2015","journal-title":"Thorax."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1007\/s12070-018-1266-y","article-title":"Evaluating hearing loss in patients undergoing second line anti tubercular treatment","volume":"71","author":"Verma","year":"2019","journal-title":"Indian J Otolaryngol Head Neck Surg."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pds.4125","article-title":"Differences in VigiBase(R) reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment","volume":"26","author":"Sagwa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/j.1749-6632.1966.tb45537.x","article-title":"The toxicity of capreomycin in laboratory animals","volume":"135","author":"Welles","year":"1966","journal-title":"Ann N Y Acad Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s11882-013-0416-2","article-title":"Efficacy and safety of long-term antibiotics (macrolides) for the treatment of chronic rhinosinusitis","volume":"14","author":"Cervin","year":"2014","journal-title":"Curr Allergy Asthma Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1128\/AAC.33.6.791","article-title":"Vancomycin- and erythromycin-induced hearing loss in humans","volume":"33","author":"Brummett","year":"1989","journal-title":"Antimicrob Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jama.1973.03220370060028","article-title":"Transient perceptive deafness due to erythromycin lactobionate","volume":"225","author":"Mintz","year":"1973","journal-title":"JAMA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/00129492-200307000-00029","article-title":"Erythromycin ototoxicity","volume":"24","author":"McGhan","year":"2003","journal-title":"Otol Neurotol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0002-9343(92)90016-5","article-title":"Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia","volume":"92","author":"Swanson","year":"1992","journal-title":"Am J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/archotol.1984.00800300050011","article-title":"Ototoxic effect of erythromycin therapy","volume":"110","author":"Schweitzer","year":"1984","journal-title":"Arch Otolaryngol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/019459988409200615","article-title":"Erythromycin ototoxicity: analysis and conclusions based on 22 case reports","volume":"92","author":"Haydon","year":"1984","journal-title":"Otolaryngol Head Neck Surg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1001\/archinte.153.7.879","article-title":"Clinically significant hearing loss in renal allograft recipients treated with intravenous erythromycin","volume":"153","author":"Vasquez","year":"1993","journal-title":"Arch Intern Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1432-2277.1994.tb01279.x","article-title":"Erythromycin ototoxicity in liver transplant patients","volume":"7","author":"Moral","year":"1994","journal-title":"Transpl Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/archinte.143.6.1263","article-title":"Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis","volume":"143","author":"Kroboth","year":"1983","journal-title":"Arch Intern Med."},{"key":"B26","first-page":"935","article-title":"Ototoxicity of erythromycin in peritoneal dialysis patients","volume":"2","author":"Taylor","year":"1981","journal-title":"Lancet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0140-6736(78)91961-X","article-title":"Ototoxicity of erythromycin","volume":"2","author":"van Marion","year":"1978","journal-title":"Lancet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/22953337.1979.11718674","article-title":"Ototoxicity of erythromycin lactobionate","volume":"34","author":"Lornoy","year":"1979","journal-title":"Acta Clin Belg."},{"key":"B29","first-page":"2283","article-title":"Transient deafness in patients with renal insufficiency treated with erythromycin","volume":"8","author":"Kanfer","year":"1979","journal-title":"Nouv Presse Med."},{"key":"B30","first-page":"60","article-title":"Erythromycin ototoxicity","volume":"9","author":"Thompson","year":"1980","journal-title":"J Otolaryngol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1001\/archinte.146.5.897","article-title":"Erythromycin ototoxicity and acute psychotic reaction in cancer patients with hepatic dysfunction","volume":"146","author":"Umstead","year":"1986","journal-title":"Arch Intern Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/0002-9378(81)90501-9","article-title":"Ototoxicity of erythromycin gluceptate","volume":"139","author":"Beckner","year":"1981","journal-title":"Am J Obstet Gynecol."},{"key":"B33","first-page":"821","article-title":"Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity","volume":"79","author":"Wallach","year":"1992","journal-title":"J Fla Med Assoc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/01050398609045952","article-title":"Irreversible ototoxic effect of erythromycin","volume":"15","author":"Levin","year":"1986","journal-title":"Scand Audiol."},{"key":"B35","first-page":"230","article-title":"Irreversible sensorineural hearing loss due to erythromycin","volume":"139","author":"Dylewski","year":"1988","journal-title":"CMAJ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/archinte.1991.00400020124025","article-title":"Ototoxic reaction to erythromycin","volume":"151","author":"Agusti","year":"1991","journal-title":"Arch Intern Med."},{"key":"B37","first-page":"186","article-title":"Ototoxicity of erythromycin in man: electrophysiologic approach","volume":"14","author":"Sacristan","year":"1993","journal-title":"Am J Otol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/000348949710600713","article-title":"Ototoxic effect of erythromycin on cochlear potentials in the guinea pig","volume":"106","author":"Kobayashi","year":"1997","journal-title":"Ann Otol Rhinol Laryngol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3109\/00016489609137891","article-title":"Inhibitory effect of erythromycin on ion transport by stria vascularis and vestibular dark cells","volume":"116","author":"Liu","year":"1996","journal-title":"Acta Otolaryngol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0025-7125(16)30040-2","article-title":"Azithromycin and clarithromycin","volume":"79","author":"Schlossberg","year":"1995","journal-title":"Med Clin North Am"},{"key":"B41","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/clinids\/23.5.983","article-title":"Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus","volume":"23","author":"Griffith","year":"1996","journal-title":"Clin Infect Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/clinids\/24.5.958","article-title":"Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease","volume":"24","author":"Brown","year":"1997","journal-title":"Clin Infect Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/000348940111000119","article-title":"Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report","volume":"110","author":"Mamikoglu","year":"2001","journal-title":"Ann Otol Rhinol Laryngol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ajhp\/56.4.380","article-title":"Azithromycin-induced hearing loss","volume":"56","author":"Lo","year":"1999","journal-title":"Am J Health Syst Pharm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(94)91030-8","article-title":"Ototoxicity with azithromycin","volume":"343","author":"Wallace","year":"1994","journal-title":"Lancet."},{"key":"B46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/clinids\/24.1.76","article-title":"Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus","volume":"24","author":"Tseng","year":"1997","journal-title":"Clin Infect Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1592\/phco.19.3.245.30930","article-title":"Intravenous azithromycin-induced ototoxicity","volume":"19","author":"Bizjak","year":"1999","journal-title":"Pharmacotherapy."},{"key":"B49","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/MAO.0000000000001887","article-title":"Azithromycin and sensorineural hearing loss in adults: a retrospective cohort study","volume":"39","author":"Alrwisan","year":"2018","journal-title":"Otol Neurotol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2310\/7070.2007.0047","article-title":"Sensorineural hearing loss as a probable serious adverse drug reaction associated with low-dose oral azithromycin","volume":"36","author":"Mick","year":"2007","journal-title":"J Otolaryngol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1177\/000348940010900416","article-title":"Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report","volume":"109","author":"Ress","year":"2000","journal-title":"Ann Otol Rhinol Laryngol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1128\/AAC.02067-13","article-title":"Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3389\/fphar.2019.01161","article-title":"Ototoxic adverse drug reactions: a disproportionality analysis using the Italian spontaneous reporting database","volume":"10","author":"Barbieri","year":"2019","journal-title":"Front Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2058738420941754","DOI":"10.1177\/2058738420941754","article-title":"Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!","volume":"34","author":"Ciorba","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1258\/0022215011908676","article-title":"Reversible ototoxic effect of azithromycin and clarithromycin on transiently evoked otoacoustic emissions in guinea pigs","volume":"115","author":"Uzun","year":"2001","journal-title":"J Laryngol Otol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/archoto.2010.54","article-title":"Ototoxicity of topical azithromycin solutions in the guinea pig","volume":"136","author":"Pawlowski","year":"2010","journal-title":"Arch Otolaryngol Head Neck Surg."},{"key":"B57","unstructured":"Does clarithromycin cause hearing loss? A 12-year review of clarithromycin therapy for nontuberculous mycobacterial lymphadenitis in children68793\n            HeffernanCB\n            McKeonMG\n            MolonyS\n            KawaiK\n            StilesDJ\n            LachenauerCS\n          10.1177\/000348941878811230032669Ann Otol Rhinol Laryngol.1272018"},{"key":"B58","doi-asserted-by":"publisher","first-page":"350","DOI":"10.2165\/00002018-199308050-00003","article-title":"Overview of the tolerability profile of clarithromycin in preclinical and clinical trials","volume":"8","author":"Guay","year":"1993","journal-title":"Drug Saf."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1128\/AAC.35.10.2049","article-title":"Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS","volume":"35","author":"Fernandez-Martin","year":"1991","journal-title":"Antimicrob Agents Chemother."},{"key":"B60","first-page":"271","article-title":"Treatment with clarithromycin of 173 HIV+ patients with disseminated Mycobacterium avium intracellulare infection","volume":"11","author":"Dautzenberg","year":"1994","journal-title":"Rev Mal Respir."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1378\/chest.107.4.1035","article-title":"Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France","volume":"107","author":"Dautzenberg","year":"1995","journal-title":"Chest."},{"key":"B62","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/archinte.1993.00410030074010","article-title":"Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome","volume":"153","author":"Dautzenberg","year":"1993","journal-title":"Arch Intern Med."},{"key":"B63","first-page":"462","article-title":"Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections a Mycobacteries","volume":"2","author":"Roussel","year":"1998","journal-title":"Int J Tuberc Lung Dis."},{"key":"B64","first-page":"1743","article-title":"Ototoxicity induced by clarithromycin","volume":"146","author":"Kolkman","year":"2002","journal-title":"Ned Tijdschr Geneeskd."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1258\/002221503322683984","article-title":"Tinnitus due to clarithromycin","volume":"117","author":"Uzun","year":"2003","journal-title":"J Laryngol Otol"},{"key":"B66","first-page":"127","article-title":"Clarithromycin induced reversible sensorineural hearing loss","volume":"7","author":"Hajiioannou","year":"2011","journal-title":"B-ENT."},{"key":"B67","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pedex.2011.07.002","article-title":"Another cause of ototoxicity: clarithromycin","volume":"6","author":"Whittemore","year":"2011","journal-title":"Int J Pediatr Otorhinolaryngol Extra."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0140-6736(20)30047-7","article-title":"Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial","volume":"395","author":"Phillips","year":"2020","journal-title":"Lancet."},{"key":"B69","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/pgmj.2004.020412","article-title":"Irreversible sensorineural hearing loss due to clarithromycin","volume":"81","author":"Coulston","year":"2005","journal-title":"Postgrad Med J."},{"key":"B70","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/lary.26190","article-title":"Risk of sensorineural hearing loss with macrolide antibiotics: A nested case-control study","volume":"127","author":"Etminan","year":"2017","journal-title":"Laryngoscope."},{"key":"B71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00002018-199920010-00004","article-title":"Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients","volume":"20","author":"Principi","year":"1999","journal-title":"Drug Saf."},{"key":"B72","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/lary.26799","article-title":"Macrolide-associated sensorineural hearing loss: a systematic review","volume":"128","author":"Ikeda","year":"2018","journal-title":"Laryngoscope."},{"key":"B73","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1128\/AAC.01088-08","article-title":"Vancomycin ototoxicity: a reevaluation in an era of increasing doses","volume":"53","author":"Forouzesh","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"B74","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/BF03259891","article-title":"Vancomycin ototoxicity and nephrotoxicity. A review","volume":"3","author":"Bailie","year":"1988","journal-title":"Med Toxicol Adverse Drug Exp."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e0224561","DOI":"10.1371\/journal.pone.0224561","article-title":"Long-term vancomycin use had low risk of ototoxicity","volume":"14","author":"Humphrey","year":"2019","journal-title":"PLoS ONE."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/S0140-6736(94)92890-8","article-title":"Why monitor peak vancomycin concentrations?","volume":"344","author":"Saunders","year":"1994","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/lary.1983.93.5.649","article-title":"Ototoxicity of oral neomycin and vancomycin","volume":"93","author":"Kavanagh","year":"1983","journal-title":"Laryngoscope."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2980913","DOI":"10.1155\/2018\/2980913","article-title":"An unusual case of ototoxicity with use of oral vancomycin","volume":"2018","author":"Gomceli","year":"2018","journal-title":"Case Rep Infect Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1345\/aph.1C145","article-title":"Sensorineural hearing loss associated with intrathecal vancomycin","volume":"37","author":"Klibanov","year":"2003","journal-title":"Ann Pharmacother."},{"key":"B80","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/QCO.0000000000000263","article-title":"Vancomycin toxicity in neonates: a review of the evidence","volume":"29","author":"Lestner","year":"2016","journal-title":"Curr Opin Infect Dis."},{"key":"B81","first-page":"17","article-title":"Vancomycin pharmacokinetics in premature infants","volume":"5","author":"Gross","year":"1985","journal-title":"Pediatr Pharmacol (New York)."},{"key":"B82","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1067\/mpd.2003.mpd037","article-title":"Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss","volume":"142","author":"de Hoog","year":"2003","journal-title":"J Pediatr."},{"key":"B83","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/0002-9378(89)90766-7","article-title":"Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant?","volume":"161","author":"Reyes","year":"1989","journal-title":"Am J Obstet Gynecol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000324857","article-title":"Are gentamicin and\/or vancomycin associated with ototoxicity in the neonate? A retrospective audit","volume":"100","author":"Vella-Brincat","year":"2011","journal-title":"Neonatology."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1093\/jac\/dkaa156","article-title":"Vancomycin-induced ototoxicity in very-low-birthweight infants","volume":"75","author":"Marissen","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"B86","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/archotol.1990.01870010065019","article-title":"Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs","volume":"116","author":"Brummett","year":"1990","journal-title":"Arch Otolaryngol Head Neck Surg."},{"key":"B87","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000276228","article-title":"Ototoxicity of vancomycin: an experimental study in guinea pigs","volume":"53","author":"Lutz","year":"1991","journal-title":"ORL J Otorhinolaryngol Relat Spec."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e00648","DOI":"10.1128\/AAC.00648-19","article-title":"Mildred rebstock: profile of the medicinal chemist who synthesized chloramphenicol","volume":"63","author":"Aronoff","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B89","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev.pa.28.040188.000503","article-title":"Chloramphenicol: relation of structure to activity and toxicity","volume":"28","author":"Yunis","year":"1988","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1017\/S0022215100147000","article-title":"Chloramphenicol ototoxicity. A case report","volume":"98","author":"Iqbal","year":"1984","journal-title":"J Laryngol Otol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4314\/njsr.v3i2.12225","article-title":"Chloramphenicol induced hearing loss","volume":"3","author":"Ogisi","year":"2001","journal-title":"Nigerian J Surg Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4103\/1119-3077.104527","article-title":"Prevalence of ototoxicity in University of Benin Teaching Hospital, Benin city: a 5-year review","volume":"15","author":"Obasikene","year":"2012","journal-title":"Niger J Clin Pract."},{"key":"B93","first-page":"256","article-title":"Ototoxicity in Nigeria: why it persists","volume":"93","author":"Kokong","year":"2014","journal-title":"Ear Nose Throat J."},{"key":"B94","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/000348946307200104","article-title":"The effects of chloramphenicol upon the electrical activity of the ear","volume":"72","author":"Patterson","year":"1963","journal-title":"Ann Otol Rhinol Laryngol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"634","DOI":"10.5694\/j.1326-5377.1975.tb106157.x","article-title":"Ototoxicity of chloramphenicol ear drops with propylene glycol as solvent","volume":"2","author":"Morizono","year":"1975","journal-title":"Med J Aust."},{"key":"B96","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1001\/archotol.1968.00760060582005","article-title":"Ototoxicity of topically applied chloramphenicol","volume":"87","author":"Proud","year":"1968","journal-title":"Arch Otolaryngol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/archotol.1967.00760040684017","article-title":"Chloramphenicol. Topical application in the middle ear","volume":"85","author":"D'Angelo","year":"1967","journal-title":"Arch Otolaryngol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/000348946407300122","article-title":"The effects of chloramphenicol upon the electrical activity of the ear. Ii. long term data","volume":"73","author":"Gulick","year":"1964","journal-title":"Ann Otol Rhinol Laryngol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.652674\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T05:57:26Z","timestamp":1615269446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.652674\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":98,"alternative-id":["10.3389\/fneur.2021.652674"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.652674","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"article-number":"652674"}}